Tenderwize
Wróć do wyszukiwania

Open-House-Biologika-Rabattverträge 2025-17 - Agalsidase beta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 29, 2027 · 308 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-17 -Agalsidase beta

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

The procedure is explicitly not a procurement under EU/German procurement law. Legal remedies are via social courts, wh...

No estimated value, no volume guarantees. Discount agreements may be unattractive if volumes are low.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of Agalsidase beta to the participating health insurance funds under discount agreements.
  • Open House procedure with no exclusivity and no negotiation.
Pokaż pełne podsumowanie

This is an Open House procedure for Rabattverträge (discount agreements) under §130a SGB V for the active ingredient Agalsidase beta. The lead buyer is Techniker Krankenkasse (TK) in cooperation with HEK and hkk. The contract is a non-exclusive framework without negotiation; no estimated value is provided. The deadline for submission is 2027-06-29, but contributions are possible at any time during the contract period (01.07.2025-30.06.2027). Only one lot is identified. The opportunity is open to all qualified pharmaceutical entrepreneurs who meet the eligibility criteria. The notice explicitly states this is not a public procurement subject to procurement law, and legal challenges go to social courts. No procurement documents were analyzed (only the XML notice).

Ryzyka

The procedure is explicitly not a procurement under EU/German procurement law. Legal remedies are via social courts, wh...

No estimated value, no volume guarantees. Discount agreements may be unattractive if volumes are low.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4(18) AMG with a valid marketing authorization for Agalsidase beta.
  • Registered seat in Germany, EU, or EEA (§9(2) AMG).

Eligibility

  • No criminal convictions or exclusion grounds (GWB §§123,124).

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria specified; contract is offered to all eligible participants without competitive award.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-17 - Agalsidase beta

Conclusion of pharmaceutical discount agreements for the active substance Agalsidase beta under the Open House procedure. No exclusivity, no negotiation, uniform conditions. Contract term 24 months (01.07.2025-30.06.2027).

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jun 2025 - Jun 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified; contract is offered to all eligible participants without competitive award.

Termin

Deadline Jun 29, 2027

Szczegóły zamówienia

Data publikacji
25 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
336062-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3